Zydus Lifesciences, formerly known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Founded in 1995, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Zydus Lifesciences focuses on research and development, manufacturing, and marketing of a diverse range of healthcare products, including generic medicines, biosimilars, and vaccines. With a commitment to innovation, Zydus Lifesciences has achieved significant milestones, such as the development of India's first indigenously produced DNA vaccine. The company is recognised for its robust portfolio of over 1,000 products, which cater to various therapeutic areas, making it a key player in the pharmaceutical market. Zydus Lifesciences continues to enhance its market position through strategic partnerships and a dedication to improving global health outcomes.
How does Zydus Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zydus Lifesciences's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Zydus Lifesciences reported total carbon emissions of approximately 328,547,000 kg CO2e, comprising 56,459,380 kg CO2e from Scope 1, 205,171,570 kg CO2e from Scope 2, and 66,915,740 kg CO2e from Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 261,630,950 kg CO2e. For the previous year, 2024, the company recorded total emissions of about 257,468,970 kg CO2e, with Scope 1 emissions at 65,458,740 kg CO2e and Scope 2 emissions at 192,010,230 kg CO2e. In 2023, Zydus Lifesciences reported emissions of approximately 10,928,000 kg CO2e in India, with Scope 1 at 3,490,000 kg CO2e and Scope 2 at 9,928,000 kg CO2e. Zydus Lifesciences has committed to achieving carbon neutrality in its operations (Scope 1 and 2 emissions) by FY2035. This long-term target reflects the company's dedication to reducing its carbon footprint and aligns with industry standards for climate action. The company is also recognised as "Committed" to net-zero emissions, indicating a proactive approach to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. Overall, Zydus Lifesciences is actively working towards significant emissions reductions while maintaining transparency in its reporting and commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zydus Lifesciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Zydus Lifesciences's sustainability data and climate commitments